Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Market Closed 08-28 16:00:00 EDT

13.24

-0.50

-3.64%

盘后13.24

+0.000.00%

19:30 EDT

High13.93	Low13.20	Vol765.43K
Open13.59	D1 Closing13.74	Amplitude5.28%
Mkt Cap1.37B	Tradable Cap1.17B	Total Shares103.52M
T/O10.21M	T/O Rate0.86%	Tradable Shares88.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":13.24,"timestamp":1787947200000,"preClose":13.74,"halted":0,"volume":765429,"hourTrading":{"tag":"盘后","latestPrice":13.24,"preClose":13.24,"latestTime":"19:30 EDT","volume":14239,"amount":188558.18,"timestamp":1787959806051,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.036390101892285295,"floatShares":88686700,"shares":103517562,"eps":-1.351255,"marketStatus":"Market Closed","change":-0.5,"latestTime":"08-28 16:00:00 EDT","open":13.59,"high":13.925,"low":13.2,"amount":10209188.669085,"amplitude":0.052766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.351255,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":13.74,"preHourTrading":{"tag":"盘前","latestPrice":13.7625,"preClose":13.74,"latestTime":"09:28 EDT","volume":5078,"amount":70230.349726,"timestamp":1787923680101,"change":0.0225,"changeRate":0.001638,"amplitude":0.093886},"postHourTrading":{"tag":"盘后","latestPrice":13.24,"preClose":13.24,"latestTime":"19:30 EDT","volume":14239,"amount":188558.18,"timestamp":1787959806051,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.704278,"impliedVol":2.0775,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/ORIC/tweets","defaultTab":"tweets","newsList":[{"id":"2663134160","title":"Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663134160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2663134160?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:12","pubTimestamp":1787947941,"startTime":"0","endTime":"0","summary":"Oric Pharma CFO Dominic Piscitelli disposes of 77,000 common shares worth $1.05 millionOric Pharmaceuticals CFO Dominic Piscitelli sold 77,000 common shares on Aug. 26 at USD 13.69.He exercised stock ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLnCNhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115860913","title":"Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1115860913","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115860913?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:02","pubTimestamp":1786608136,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the \"Drug Clinical Trial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC","IBBJ","BK0239","IBBQ","MDTX","PSYK","BMED","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935247","title":"Oric Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935247?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:02","pubTimestamp":1786363320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980560","title":"Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980560?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:40","pubTimestamp":1786358411,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC), Janux Therapeutics In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-janux-therapeutics-inc-janx-and-entrada-therapeutics-inc-trda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-janux-therapeutics-inc-janx-and-entrada-therapeutics-inc-trda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ORIC","BK4139","JANX","BK4581","XLV","HCSG","LU0128526141.USD","TRDA","LU0029874061.USD","BK4539","BK4585","BK4137","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657261416","title":"Oric Pharma Grants 125,400 Stock Options, 20,550 RSUs to Five New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2657261416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657261416?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134634,"startTime":"0","endTime":"0","summary":"Oric Pharma grants 125,400 stock options, 20,550 RSUs to five new employeesOric Pharmaceuticals issued inducement equity awards dated Aug. 3, 2026 to five new non-executive hires who started in July 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL61s2Rl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","ORIC","BCDF","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","BK4588","BK4139","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626113","title":"Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626113?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUAMCHCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622535","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622535","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622535?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug.  07, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341394/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155087","title":"Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155087","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155087?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:29","pubTimestamp":1785857348,"startTime":"0","endTime":"0","summary":"In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Kasimov ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554627","title":"Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554627?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:50","pubTimestamp":1785851432,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-clearpoint-neuro-clpt-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-clearpoint-neuro-clpt-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","CLPT","KROS","HCSG","XBI","BK4082","XLV","LABU","BK4588","LU0128526141.USD","BK4581","BK4139","ORIC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656355120","title":"ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2656355120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656355120?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:40","pubTimestamp":1785850801,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Boris Pe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-reaffirmed-with-unchanged-25-price-target-on-multiple-oncology-catalysts-and-mcrpc-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-reaffirmed-with-unchanged-25-price-target-on-multiple-oncology-catalysts-and-mcrpc-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302166","title":"Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302166?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:59","pubTimestamp":1785790752,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLXLM4967:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302187","title":"ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302187","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302187?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:57","pubTimestamp":1785790664,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60892053/oric-pharmaceuticals-q2-eps-0-38-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656030469","title":"Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2656030469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656030469?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:23","pubTimestamp":1785788625,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPCOric Pharmaceuticals initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3yGXwG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078673","title":"ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337877/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","GDOC","HYLG","BK4139","NVIB","IDNA","LNGX","ORIC","MEDX","AR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655381385","title":"Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655381385","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655381385?lang=en_us&edition=fundamental","pubTime":"2026-07-31 05:20","pubTimestamp":1785446421,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals expands 2022 inducement equity plan share pool by 1,100,000 sharesOric Pharmaceuticals adopted an amended and restated 2022 Inducement Equity Incentive Plan effective July 28, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL1bb75b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655880981","title":"Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2655880981","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655880981?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:16","pubTimestamp":1785269766,"startTime":"0","endTime":"0","summary":"Oric Pharma director Richard A. Heyman disposes of 13,100 common shares worth $157,462.00Oric Pharmaceuticals director Richard A. Heyman sold 13,100 shares on July 24 at USD 12.02.He exercised options","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL539f3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652156602","title":"ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652156602","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652156602?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:30","pubTimestamp":1784550600,"startTime":"0","endTime":"0","summary":"Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalaya","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329711/0/en/ORIC-Pharmaceuticals-Announces-Three-Presentations-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651891994","title":"Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')","url":"https://stock-news.laohu8.com/highlight/detail?id=2651891994","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651891994?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:20","pubTimestamp":1784060448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nL8N43G2HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651534489","title":"Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651534489","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651534489?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:07","pubTimestamp":1784059625,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals signs trial collaboration with Bayer for Nubeqa supply in Phase 3 prostate cancer studyOric Pharmaceuticals entered a clinical trial collaboration and supply agreement with Bayer ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL2K3dKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4585","BCDF","LU2095319765.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","ORIC","SG9999014005.SGD","LU0314104364.USD","SG9999014013.SGD","BK4588","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651848989","title":"Oric® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in Mcrpc Evaluating Rinzimetostat in Combination with Nubeqa® (darolutamide), Supported by Clinical Collaboration with Bayer","url":"https://stock-news.laohu8.com/highlight/detail?id=2651848989","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651848989?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:05","pubTimestamp":1784059502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA8JCRZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.0676},{"period":"1month","weight":0.1738},{"period":"3month","weight":0.5669},{"period":"6month","weight":-0.0156},{"period":"1year","weight":0.32},{"period":"ytd","weight":0.6186}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.047029},{"month":6,"riseRate":0.714286,"avgChangeRate":0.161131},{"month":7,"riseRate":0.428571,"avgChangeRate":0.002728},{"month":8,"riseRate":0.714286,"avgChangeRate":0.105711},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}